138 related articles for article (PubMed ID: 22740853)
1. NY-ESO-1 expression in hepatocellular carcinoma: A potential new marker for early recurrence after surgery.
Xu H; Gu N; Liu ZB; Zheng M; Xiong F; Wang SY; Li N; Lu J
Oncol Lett; 2012 Jan; 3(1):39-44. PubMed ID: 22740853
[TBL] [Abstract][Full Text] [Related]
2. Expression of SSX-1 and NY-ESO-1 mRNA in tumor tissues and its corresponding peripheral blood expression in patients with hepatocellular carcinoma.
Lu Y; Wu LQ; Lü ZH; Wang XJ; Yang JY
Chin Med J (Engl); 2007 Jun; 120(12):1042-6. PubMed ID: 17637219
[TBL] [Abstract][Full Text] [Related]
3. [Correlation of NY-ESO-1 gene and protein expression to metastasis and clinicopathologic features of hepatocellular carcinoma].
Zhang WM; Xiao G; Xie D; Zhang M; Guo AL; Wen JM
Ai Zheng; 2005 May; 24(5):622-6. PubMed ID: 15890110
[TBL] [Abstract][Full Text] [Related]
4. Spontaneous tumor-specific humoral and cellular immune responses to NY-ESO-1 in hepatocellular carcinoma.
Korangy F; Ormandy LA; Bleck JS; Klempnauer J; Wilkens L; Manns MP; Greten TF
Clin Cancer Res; 2004 Jul; 10(13):4332-41. PubMed ID: 15240519
[TBL] [Abstract][Full Text] [Related]
5. The spontaneous CD8+ T-cell response to HLA-A2-restricted NY-ESO-1b peptide in hepatocellular carcinoma patients.
Shang XY; Chen HS; Zhang HG; Pang XW; Qiao H; Peng JR; Qin LL; Fei R; Mei MH; Leng XS; Gnjatic S; Ritter G; Simpson AJ; Old LJ; Chen WF
Clin Cancer Res; 2004 Oct; 10(20):6946-55. PubMed ID: 15501973
[TBL] [Abstract][Full Text] [Related]
6. [Expression of NY-ESO-1 and LAGE-1 cancer-testis antigens in hepatocellular carcinoma].
Zhang WM; Xiao G; Zhang M; Guo AL; Dong Y; Wen JM
Zhonghua Bing Li Xue Za Zhi; 2005 Apr; 34(4):202-5. PubMed ID: 16091172
[TBL] [Abstract][Full Text] [Related]
7. [Expression of NY-ESO-1/LAGE-1 genes in hepatocellular carcinoma and autologous humoral responses induced thereby].
Xing BC; Yuan YH; Hu ZG; Liu YX; Han Y; Liu N; Chen WF; Wang Y
Zhonghua Yi Xue Za Zhi; 2004 Dec; 84(23):1980-2. PubMed ID: 15730810
[TBL] [Abstract][Full Text] [Related]
8. Combined cancer testis antigens enhanced prediction accuracy for prognosis of patients with hepatocellular carcinoma.
Wang M; Li J; Wang L; Chen X; Zhang Z; Yue D; Ping Y; Shi X; Huang L; Zhang T; Yang L; Zhao Y; Ma X; Li D; Fan Z; Zhao L; Tang Z; Zhai W; Zhang B; Zhang Y
Int J Clin Exp Pathol; 2015; 8(4):3513-28. PubMed ID: 26097535
[TBL] [Abstract][Full Text] [Related]
9. Analysis of cancer/testis antigens in sporadic medullary thyroid carcinoma: expression and humoral response to NY-ESO-1.
Maio M; Coral S; Sigalotti L; Elisei R; Romei C; Rossi G; Cortini E; Colizzi F; Fenzi G; Altomonte M; Pinchera A; Vitale M
J Clin Endocrinol Metab; 2003 Feb; 88(2):748-54. PubMed ID: 12574209
[TBL] [Abstract][Full Text] [Related]
10. NY-ESO-1 and LAGE-1 cancer-testis antigens are potential targets for immunotherapy in epithelial ovarian cancer.
Odunsi K; Jungbluth AA; Stockert E; Qian F; Gnjatic S; Tammela J; Intengan M; Beck A; Keitz B; Santiago D; Williamson B; Scanlan MJ; Ritter G; Chen YT; Driscoll D; Sood A; Lele S; Old LJ
Cancer Res; 2003 Sep; 63(18):6076-83. PubMed ID: 14522938
[TBL] [Abstract][Full Text] [Related]
11. [Estimation of an NY-ESO-1 expressing HCC cell line by NY-ESO-1b specific CD8+T cells in vitro induced by HLA-A2 restricted NY-ESO-1b peptide].
Qiao H; Qian XP; Zhang HG; Tian C; Chen WF
Beijing Da Xue Xue Bao Yi Xue Ban; 2005 Dec; 37(6):565-8. PubMed ID: 16378102
[TBL] [Abstract][Full Text] [Related]
12. Comparisons for detecting NY-ESO-1 mRNA expression levels in hepatocellular carcinoma tissues.
Wang XY; Chen HS; Luo S; Zhang HH; Fei R; Cai J
Oncol Rep; 2009 Mar; 21(3):713-9. PubMed ID: 19212631
[TBL] [Abstract][Full Text] [Related]
13. Expression of cancer/testis antigens in salivary gland carcinomas with reference to MAGE-A and NY-ESO-1 expression in adenoid cystic carcinoma.
Beppu S; Ito Y; Fujii K; Saida K; Takino H; Masaki A; Murase T; Kusafuka K; Iida Y; Onitsuka T; Yatabe Y; Hanai N; Hasegawa Y; Ijichi K; Murakami S; Inagaki H
Histopathology; 2017 Aug; 71(2):305-315. PubMed ID: 28370175
[TBL] [Abstract][Full Text] [Related]
14. Expression and immunogenicity of NY-ESO-1 in hepatocellular carcinoma.
Nakamura S; Nouso K; Noguchi Y; Higashi T; Ono T; Jungbluth A; Chen YT; Old LJ; Nakayama E; Shiratori Y
J Gastroenterol Hepatol; 2006 Aug; 21(8):1281-5. PubMed ID: 16872310
[TBL] [Abstract][Full Text] [Related]
15. Immunohystochemical expression of cancer/testis antigens (MAGE-A3/4, NY-ESO-1) in non-small cell lung cancer: the relationship with clinical-pathological features.
Grah J; Samija M; Juretić A; Sarcević B; Sobat H
Coll Antropol; 2008 Sep; 32(3):731-6. PubMed ID: 18982744
[TBL] [Abstract][Full Text] [Related]
16. Predictive and prognostic effect of CD133 and cancer-testis antigens in stage Ib-IIIA non-small cell lung cancer.
Su C; Xu Y; Li X; Ren S; Zhao C; Hou L; Ye Z; Zhou C
Int J Clin Exp Pathol; 2015; 8(5):5509-18. PubMed ID: 26191258
[TBL] [Abstract][Full Text] [Related]
17. Frequency of NY-ESO-1 and LAGE-1 expression in bladder cancer and evidence of a new NY-ESO-1 T-cell epitope in a patient with bladder cancer.
Sharma P; Gnjatic S; Jungbluth AA; Williamson B; Herr H; Stockert E; Dalbagni G; Donat SM; Reuter VE; Santiago D; Chen YT; Bajorin DF; Old LJ
Cancer Immun; 2003 Dec; 3():19. PubMed ID: 14680360
[TBL] [Abstract][Full Text] [Related]
18. Cancer-testis antigen expression in synovial sarcoma: NY-ESO-1, PRAME, MAGEA4, and MAGEA1.
Iura K; Maekawa A; Kohashi K; Ishii T; Bekki H; Otsuka H; Yamada Y; Yamamoto H; Harimaya K; Iwamoto Y; Oda Y
Hum Pathol; 2017 Mar; 61():130-139. PubMed ID: 27993576
[TBL] [Abstract][Full Text] [Related]
19. Expression and possible prognostic role of MAGE-A4, NY-ESO-1, and HER-2 antigens in women with relapsing invasive ductal breast cancer: retrospective immunohistochemical study.
Bandić D; Juretić A; Sarcević B; Separović V; Kujundzić-Tiljak M; Hudolin T; Spagnoli GC; Cović D; Samija M
Croat Med J; 2006 Feb; 47(1):32-41. PubMed ID: 16489695
[TBL] [Abstract][Full Text] [Related]
20. NY-ESO-1 cancer testis antigen demonstrates high immunogenicity in triple negative breast cancer.
Ademuyiwa FO; Bshara W; Attwood K; Morrison C; Edge SB; Karpf AR; James SA; Ambrosone CB; O'Connor TL; Levine EG; Miliotto A; Ritter E; Ritter G; Gnjatic S; Odunsi K
PLoS One; 2012; 7(6):e38783. PubMed ID: 22761704
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
